To estimate effectiveness of PCV13 among adults aged ≥65 years against all-cause lower respiratory tract infection (LRTI) and pneumonia
Latest Information Update: 07 Jan 2022
At a glance
- Drugs Pneumococcal 13-valent CRM197 vaccine conjugate (Primary)
- Indications Lower urinary tract symptoms; Pneumococcal infections
- Focus Therapeutic Use
Most Recent Events
- 07 Jan 2022 New trial record
- 30 Dec 2021 Results published in the Clinical Infectious Diseases